Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea
Open Access
- 1 January 2021
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
Abstract
Background: Anti-tumor necrosis factor (TNF) agents are increasingly used for rheumatic diseases and inflammatory bowel disease (IBD), but are associated with the development of anti-TNF-induced lupus (ATIL). Nonetheless, few ATIL studies on non-Caucasian IBD patients exist. Here, we investigated the incidence, clinical features, and risk factors of ATIL in Korea. Methods: We retrospectively reviewed the medical records of IBD patients undergoing anti-TNF therapy at our tertiary IBD center between 2008 and 2020. ATIL was diagnosed as a temporal association between symptoms and anti-TNF agents, and the presence of at least one serologic and non-serologic American College of Rheumatology criterion. The risk factors for ATIL occurrence were assessed using multivariate Cox regression analysis. Results: Of 1362 IBD patients treated with anti-TNF agents, 50 (3.7%) ATIL cases were suspected, of which 14 (1.0%) received a definitive diagnosis. Arthritis and mucocutaneous symptoms were observed in 13 and 4 patients, respectively. All ATIL cases were positive for anti-nuclear and anti-dsDNA antibodies. Four patients (30.8%) improved while continuing anti-TNF therapy. At the final follow up, the ATIL group ( n = 14) had a lower IBD remission rate (30.8% versus 68.8%, p = 0.019) than the non-ATIL group ( n = 36). Ulcerative colitis and longer disease duration were associated with ATIL occurrence, with hazard ratios of 7.017 ( p = 0.005) and 1.118 ( p = 0.002), respectively. Conclusion: Although rare, ATIL is associated with poor treatment response to IBD in Korean patients. ATIL should be considered if arthritis and mucocutaneous symptoms develop during anti-TNF therapy for IBD.Keywords
This publication has 34 references indexed in Scilit:
- Anti-Tumor Necrosis Factor-α Induced Systemic Lupus ErythematosusThe Open Rheumatology Journal, 2012
- Changes of the cytokine profile in inflammatory bowel diseasesWorld Journal of Gastroenterology, 2012
- TNF alpha antagonist‐induced lupus‐like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonistsInternational Journal of Dermatology, 2011
- Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical studyArthritis Research & Therapy, 2011
- Lupus-Like Syndrome Attributable to Anti—Tumor Necrosis Factor α Therapy in 14 Patients During an 8-Year Period at Mayo ClinicMayo Clinic Proceedings, 2009
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative ColitisInflammatory Bowel Diseases, 2008
- Autoimmune Diseases Induced by TNF-Targeted TherapiesMedicine, 2007
- Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2005
- A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumabJournal of Dermatological Treatment, 2004
- Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathyArthritis & Rheumatism, 2003